Connected Drug Delivery Devices Market Poised for Strong Growth Through 2035, Driven by Connectivity Innovation, Expanding Therapeutic Applications and Global Adoption

A ResearchAndMarkets report projects growth in the global connected drug delivery devices market from a stated base of USD 5 billion, although the article text is truncated before providing the forecast endpoint, CAGR, or detailed drivers. The report highlights connected delivery devices across device types, connectivity modes, administration routes, therapeutic areas, and regions, signaling continued demand for digitally enabled healthcare technologies.

Analysis

This is a low-signal market-research release rather than a company-specific demand datapoint, and it does not warrant a directional position by itself. The investable issue is whether connected delivery shifts recurring economics toward device-enabled adherence platforms: higher persistence can expand lifetime drug value for GLP-1, immunology and specialty-drug manufacturers, while connected-device suppliers may gain consumables, software and data-service revenue rather than merely one-time hardware sales.

Potential strategic beneficiaries include Insulet (PODD), Dexcom (DXCM), Medtronic (MDT) and Tandem Diabetes Care (TNDM), but their exposure is highly unequal and mostly concentrated in diabetes rather than the broader thematic category. The more material 6-18 month question is reimbursement: payer recognition of reduced discontinuation, hospitalization or drug waste would permit device makers to capture value; absent this, connectivity is likely absorbed as a feature with limited incremental pricing power. Large pharma companies such as Novo Nordisk (NVO), Eli Lilly (LLY) and Amgen (AMGN) could eventually use connected injectors to defend adherence and differentiation, but any benefit is unlikely to move consolidated earnings without disclosed deployment volumes.

Consensus may overvalue the hardware narrative. Commodity sensors, interoperability requirements and payer procurement can shift bargaining power to pharmaceutical sponsors and distributors, pressuring standalone device gross margins even as unit volumes rise. A credible catalyst would be an FDA-cleared connected injector tied to a high-value self-administered drug plus explicit reimbursement or persistence data; falsification would be flat device ASPs, no recurring software revenue disclosure, or evidence that pharmacy-channel substitution captures the economics.

Key Decisions for Investors

• No new thematic position on this release; treat it as an alert only. Require company-specific evidence of reimbursed connected-device launches, segment revenue guidance, or disclosed adherence outcomes before underwriting earnings impact.
• Monitor PODD and DXCM over the next 1-3 quarters for recurring-revenue mix, payer coverage expansion and gross-margin trajectory. A long is more defensible only if connectivity produces pricing or retention gains rather than higher R&D and customer-acquisition expense.
• For a 6-18 month watchlist, track NVO and LLY device-enabled delivery programs against their injectable franchises. Consider a relative-value long NVO or LLY versus a broad medtech proxy such as IHI only after a product-specific reimbursement catalyst; the key risk is that device differentiation is competed away and does not improve persistence.
• Avoid shorting incumbent device makers solely on the premise of hardware commoditization. A short thesis requires confirming evidence such as ASP declines, payer exclusions, deteriorating sensor/pump attach rates, or a pharma-owned delivery platform that bypasses the incumbent ecosystem.